SCHEMBL14849784

SCHEMBL14849784

CNC(=O)N1C[C@H](c2[nH]c(-c3ccc(Cl)cc3)nc2-c2ncccn2)CC[C@@H]1c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRCP P42785 5/20 0.59
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ CXCR3 P49682 1/20 0.34
▸ HSD11B1 P28845 1/20 0.34
▸ FFAR2 O15552 1/20 0.34
▸ P2RX7 Q99572 1/20 0.34
▸ RAF1 P04049 2/20 0.33
▸ PROKR1 Q8TCW9 2/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ NFKB1 P19838 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ NFKB2 Q00653 1/20 0.33
▸ RELA Q04206 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ MAPK13 O15264 1/20 0.33
▸ MAPK12 P53778 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14849787 1.00 PRCP (0.59) PRCPMEN1KMT2ACXCR3HSD11B1
SCHEMBL14840577 0.90 PRCP (0.63) PRCPHSD11B1FFAR2RAF1MAPK13
SCHEMBL14849808 0.90 PRCP (0.59) PRCPMEN1KMT2AHSD11B1FFAR2
SCHEMBL14849812 0.90 PRCP (0.59) PRCPMEN1KMT2AHSD11B1FFAR2
SCHEMBL16512920 0.76 PRCP (0.49) PRCPRAF1MAPK13MAPK12MAPK11
SCHEMBL14840859 0.75 PRCP (0.66) PRCPHSD11B1MAPK11MAPK14
SCHEMBL14849806 0.75 PRCP (1.00) PRCP
SCHEMBL14849769 0.75 PRCP (1.00) PRCP
SCHEMBL14849781 0.74 PRCP (1.00) PRCPRAF1MAPK13MAPK12MAPK11
SCHEMBL14849783 0.74 PRCP (1.00) PRCPRAF1MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9006268-B2 Prolylcarboxypeptidase inhibitors MERCK SHARP & DOHME CORP. (US) 2015-04-14 — — US disclosed
US-9006268-B2 Prolylcarboxypeptidase inhibitors MERCK SHARP & DOHME CORP. (US) 2015-04-14 — — US disclosed
US-20130090324-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME LLC 2013-04-11 — — US disclosed
US-20130090324-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME LLC 2013-04-11 — — US disclosed
WO-2011156246-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-12-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090324-A1 NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS PRCP, PREP, ENPEP PRCP 1/4885MEN1 3238/4885KMT2A 2172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback